229 related articles for article (PubMed ID: 22785249)
1. Better outcome of patients undergoing enteral tube feeding after myeloablative conditioning for allogeneic stem cell transplantation.
Seguy D; Duhamel A; Rejeb MB; Gomez E; Buhl ND; Bruno B; Cortot A; Yakoub-Agha I
Transplantation; 2012 Aug; 94(3):287-94. PubMed ID: 22785249
[TBL] [Abstract][Full Text] [Related]
2. Enteral feeding and early outcomes of patients undergoing allogeneic stem cell transplantation following myeloablative conditioning.
Seguy D; Berthon C; Micol JB; Darré S; Dalle JH; Neuville S; Bauters F; Jouet JP; Yakoub-Agha I
Transplantation; 2006 Sep; 82(6):835-9. PubMed ID: 17006332
[TBL] [Abstract][Full Text] [Related]
3. Enteral nutrition: a first option for nutritional support of children following allo-SCT?
Azarnoush S; Bruno B; Beghin L; Guimber D; Nelken B; Yakoub-Agha I; Seguy D
Bone Marrow Transplant; 2012 Sep; 47(9):1191-5. PubMed ID: 22231466
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
Satwani P; Baldinger L; Freedman J; Jacobson JS; Guerra J; van de Ven C; Morris E; Garvin J; George D; Bradley MB; Bhatia M; Tallamy B; Schwartz J; Jin Z; Cairo MS
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083
[TBL] [Abstract][Full Text] [Related]
6. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
[TBL] [Abstract][Full Text] [Related]
7. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
8. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
9. Enteral versus parenteral nutritional support in allogeneic haematopoietic stem-cell transplantation.
Guièze R; Lemal R; Cabrespine A; Hermet E; Tournilhac O; Combal C; Bay JO; Bouteloup C
Clin Nutr; 2014 Jun; 33(3):533-8. PubMed ID: 23938114
[TBL] [Abstract][Full Text] [Related]
10. Cord blood transplantation from unrelated donors for children with acute lymphoblastic leukemia in Japan: the impact of methotrexate on clinical outcomes.
Kato K; Yoshimi A; Ito E; Oki K; Hara J; Nagatoshi Y; Kikuchi A; Kobayashi R; Nagamura-Inoue T; Kai S; Azuma H; Takanashi M; Isoyama K; Kato S;
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1814-21. PubMed ID: 21664471
[TBL] [Abstract][Full Text] [Related]
11. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
13. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.
Khabori MA; El-Emary M; Xu W; Guyatt G; Galal A; Kuruvilla J; Lipton J; Messner H; Gupta V
Bone Marrow Transplant; 2011 Apr; 46(4):516-22. PubMed ID: 20622907
[TBL] [Abstract][Full Text] [Related]
14. When early enteral feeding is not possible in critically ill patients: results of a multicenter observational study.
Cahill NE; Murch L; Jeejeebhoy K; McClave SA; Day AG; Wang M; Heyland DK
JPEN J Parenter Enteral Nutr; 2011 Mar; 35(2):160-8. PubMed ID: 21378245
[TBL] [Abstract][Full Text] [Related]
15. Better early outcome with enteral rather than parenteral nutrition in children undergoing MAC allo-SCT.
Gonzales F; Bruno B; Alarcón Fuentes M; De Berranger E; Guimber D; Behal H; Gandemer V; Spiegel A; Sirvent A; Yakoub-Agha I; Nelken B; Duhamel A; Seguy D
Clin Nutr; 2018 Dec; 37(6 Pt A):2113-2121. PubMed ID: 29097037
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
17. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
18. A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioning.
Gupta V; Panzarella T; Li L; Khan J; Sharma A; Lipton JH; Kuruvilla J; Messner H; Alibhai SM
Biol Blood Marrow Transplant; 2012 Jan; 18(1):113-24. PubMed ID: 21703974
[TBL] [Abstract][Full Text] [Related]
19. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
Ferrá C; Sanz J; de la Cámara R; Sanz G; Bermúdez A; Valcárcel D; Rovira M; Serrano D; Caballero D; Espigado I; Morgades M; Heras I; Solano C; Duarte R; Barrenetxea C; García-Noblejas A; Díez-Martin JL; Iriondo A; Carreras E; Sierra J; Sanz MA; Ribera JM;
Biol Blood Marrow Transplant; 2010 Jul; 16(7):957-66. PubMed ID: 20144909
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]